Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.

Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. J Natl Compr Canc Netw. 2019 Oct 01;17(10):1194-1202 Authors: Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ Abstract BACKGROUND: Provider experience, or clinical volume, is associated with improved outcomes in many complex healthcare settings. Despite increased complexity of anticancer therapies, studies evaluating physician-level experience and cancer treatment outcomes are lacking. METHODS: A population-based study was conducted of older adults (aged ≥66 years) diagnosed with B-cell non-Hodgkin's lymphoma in 2004 through 2011 using SEER-Medicare data. Analysis focused on outcomes in patients receiving rituximab, the first approved monoclonal anticancer immunotherapy. We hypothesized that lower physician experience using rituximab and managing its infusion-related reactions would be associated with early treatment discontinuation. A 12-month look-back from each initiation of rituximab was used to categorize physician volume (0, 1-2, or ≥3 initiations per year). Modified Poisson regression was used to account for provider-level correlation and estimated relative risk (RR) of early rituximab discontinuation (
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Related Links:

Conclusion: These findings suggest that a pro-inflammatory diet is a risk factor for prostate cancer and also can have the impact on body composition.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Conclusion: Taken together, AFPE that acts at a low micromolar range against breast cancer cells may be considered as a promising candidate for anticancer therapy.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Since Invitae’s inception a decade ago, the firm has been working for the proactive use of genetic information in mainstream medicine. The San Francisco, CA-based company has been using M&A activity to help bring companies under its tent to help make this goal a reality. On Monday, the genetic-testing specialist made more progress on this front by announcing it would put down $50 million to acquire Clear Genetics, a company that develops digital counseling software. San Francisco, CA-based Clear Genetics has developed Gia, a chatbot that equips patients with actionable information throughout the genetic t...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Software Source Type: news
John Davies' blood cells will be genetically modified in a US lab in the hope of curing him.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
Abstract Myeloid-derived suppressor cells (MDSCs) have emerged as a new immune regulator at the feto-maternal interface. Although the phenotypes and functions of these cells were primarily studied in pathological conditions such as cancers and infections, new evidence has underscored their beneficial roles in homeostasis and physiological circumstances such as normal pregnancy. In this regard, studies have shown an increased number of MDSCs, particularly granulocytic MDSCs, at the feto-maternal interface. These cells participate in maintaining immunological tolerance between mother and semi-allograft fetus through...
Source: Cellular Immunology - Category: Allergy & Immunology Authors: Tags: Cell Immunol Source Type: research
Publication date: Available online 10 November 2019Source: Seminars in Cancer BiologyAuthor(s): Jessica Burns, Christopher P Wilding, Robin L Jones, Paul H HuangAbstractSarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regimens have been made over the past few decades. Proteomics techniques are being increasingly utilised in the field of sarcoma research. Proteomic research efforts h...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
(Elsevier) A new study in The American Journal of Pathology, published by Elsevier, reports that medroxyprogesterone acetate (MPA), the active ingredient in the common contraceptive injection Depo-Provera, was effective in preventing the development of cervical cancer in mice with precancerous lesions. The drug also decreased existing precancerous lesions. If proven effective clinically, MPA may be a boon to women who do not have access to human papillomavirus (HPV) vaccines.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusions: Tacrolimus is effective in treating refractory multi-drug resistant NS with favorable outcomes in childhood onset NS. PMID: 31705749 [PubMed - in process]
Source: Iranian Journal of Kidney Diseases - Category: Urology & Nephrology Tags: Iran J Kidney Dis Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Contributors : Zintis Inde ; Giovanni C Forcina ; Kyle Denton ; Scott J DixonSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAnti-cancer drugs and other lethal agents can induce heterogeneous cell death responses in a population of cancer cells, a phenomenon referred to as fractional killing (FK). FK is often studied on a cell-by-cell basis in response to one or a limited number of stimuli. Here, we develop and validate methods to quantify FK in a high-throughput manner using population-level time-lapse measurements and mathematical modelling. Using this approach, we find that FK is h...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Cancer | Cancer & Oncology | Huntington's Disease | Immunotherapy | Lymphoma | Medicare | Non-Hodgkin's Lymphoma | Rituxan | Study